Factors of importance for a successful delivery system for proteins

Research output: Contribution to journal › Review › Research › peer-review

Standard

Factors of importance for a successful delivery system for proteins. / van de Weert, Marco; Jorgensen, Lene; Horn Moeller, Eva; Frokjaer, Sven.

In: Expert Opinion on Drug Delivery, Vol. 2, No. 6, 11.2005, p. 1029-37.

Research output: Contribution to journal › Review › Research › peer-review

Harvard

van de Weert, M, Jorgensen, L, Horn Moeller, E & Frokjaer, S 2005, 'Factors of importance for a successful delivery system for proteins', Expert Opinion on Drug Delivery, vol. 2, no. 6, pp. 1029-37. https://doi.org/10.1517/17425247.2.6.1029

APA

van de Weert, M., Jorgensen, L., Horn Moeller, E., & Frokjaer, S. (2005). Factors of importance for a successful delivery system for proteins. Expert Opinion on Drug Delivery, 2(6), 1029-37. https://doi.org/10.1517/17425247.2.6.1029

Vancouver

van de Weert M, Jorgensen L, Horn Moeller E, Frokjaer S. Factors of importance for a successful delivery system for proteins. Expert Opinion on Drug Delivery. 2005 Nov;2(6):1029-37. https://doi.org/10.1517/17425247.2.6.1029

Author

van de Weert, Marco ; Jorgensen, Lene ; Horn Moeller, Eva ; Frokjaer, Sven. / Factors of importance for a successful delivery system for proteins. In: Expert Opinion on Drug Delivery. 2005 ; Vol. 2, No. 6. pp. 1029-37.

Bibtex

@article{f576bfcf3f7e4311a25d8ddcbc4d8f16,
title = "Factors of importance for a successful delivery system for proteins",
abstract = "Protein pharmaceuticals have matured into an important class of drugs, now comprising one in three novel drugs introduced on the market. However, significant gains are still to be made in reducing the costs of production, ensuring proper pharmacokinetics and efficacy, increasing patient compliance and convenience, and reducing side effects such as immunogenicity. This review summarises these issues and provides recent examples of methods to reduce costs, alter pharmacokinetics and increase patient compliance. It also discusses the increasing interest in understanding immunogenicity in order to prevent failure of the protein drug or serious life-threatening side effects due to autoimmunogenicity.",
keywords = "Animals, Antibody Formation, Chemistry, Pharmaceutical, Drug Administration Routes, Drug Delivery Systems, Drug Stability, Erythropoietin, Humans, Patient Compliance, Proteins, Recombinant Proteins, Red-Cell Aplasia, Pure",
author = "{van de Weert}, Marco and Lene Jorgensen and {Horn Moeller}, Eva and Sven Frokjaer",
year = "2005",
month = nov,
doi = "10.1517/17425247.2.6.1029",
language = "English",
volume = "2",
pages = "1029--37",
journal = "Expert Opinion on Drug Delivery",
issn = "1742-5247",
publisher = "Taylor & Francis",
number = "6",

}

RIS

TY - JOUR

T1 - Factors of importance for a successful delivery system for proteins

AU - van de Weert, Marco

AU - Jorgensen, Lene

AU - Horn Moeller, Eva

AU - Frokjaer, Sven

PY - 2005/11

Y1 - 2005/11

N2 - Protein pharmaceuticals have matured into an important class of drugs, now comprising one in three novel drugs introduced on the market. However, significant gains are still to be made in reducing the costs of production, ensuring proper pharmacokinetics and efficacy, increasing patient compliance and convenience, and reducing side effects such as immunogenicity. This review summarises these issues and provides recent examples of methods to reduce costs, alter pharmacokinetics and increase patient compliance. It also discusses the increasing interest in understanding immunogenicity in order to prevent failure of the protein drug or serious life-threatening side effects due to autoimmunogenicity.

AB - Protein pharmaceuticals have matured into an important class of drugs, now comprising one in three novel drugs introduced on the market. However, significant gains are still to be made in reducing the costs of production, ensuring proper pharmacokinetics and efficacy, increasing patient compliance and convenience, and reducing side effects such as immunogenicity. This review summarises these issues and provides recent examples of methods to reduce costs, alter pharmacokinetics and increase patient compliance. It also discusses the increasing interest in understanding immunogenicity in order to prevent failure of the protein drug or serious life-threatening side effects due to autoimmunogenicity.

KW - Animals

KW - Antibody Formation

KW - Chemistry, Pharmaceutical

KW - Drug Administration Routes

KW - Drug Delivery Systems

KW - Drug Stability

KW - Erythropoietin

KW - Humans

KW - Patient Compliance

KW - Proteins

KW - Recombinant Proteins

KW - Red-Cell Aplasia, Pure

U2 - 10.1517/17425247.2.6.1029

DO - 10.1517/17425247.2.6.1029

M3 - Review

C2 - 16296807

VL - 2

SP - 1029

EP - 1037

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 6

ER -

ID: 44640488